Delving into the Latest Updates on Shanghai JMT Biological Technology Co Ltd with Synapse

Overview

Tags

Neoplasms

Respiratory Diseases

Skin and Musculoskeletal Diseases

Monoclonal antibody

Bispecific antibody

Antibody fusion proteins

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6
Hemic and Lymphatic Diseases	4
Immune System Diseases	3
Endocrinology and Metabolic Disease	3

Top 5 Drug Type	Count

Monoclonal antibody	4
Fusion protein	2
Small molecule drug	1
Bispecific antibody	1
Antibody fusion proteins	1

Top 5 Target	Count

SIRPα(Signal-regulatory protein alpha)	1
GPC3 x IFN α	1
GFRAL(GDNF family receptor alpha like)	1
RANKL(Tumor necrosis factor ligand superfamily member 11)	1
HER2(Receptor tyrosine-protein kinase erbB-2)	1

[Translation] A randomized, controlled, open-label phase III clinical study of JMT101 combined with osimertinib versus osimertinib as first-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) sensitive mutations

主要目的：评价JMT101联合奥希替尼对比奥希替尼一线治疗携带EGFR敏感突变晚期NSCLC的疗效差异；次要目的：评价JMT101联合奥希替尼对比奥希替尼一线治疗携带EGFR敏感突变晚期NSCLC的疗效；评价JMT101联合奥希替尼对比奥希替尼一线治疗携带EGFR敏感突变晚期NSCLC的安全性；评价JMT101的药代动力学特征；评价JMT101的免疫原性；分析EGFR突变状态、表达水平、扩增状态与临床疗效之间的相关性；分析肿瘤相关基因改变与临床疗效之间的相关性。

[Translation]

Primary purpose: To evaluate the efficacy of JMT101 combined with osimertinib versus osimertinib as first-line treatment for advanced NSCLC with EGFR sensitive mutations; Secondary purpose: To evaluate the efficacy of JMT101 combined with osimertinib versus osimertinib as first-line treatment for advanced NSCLC with EGFR sensitive mutations; To evaluate the safety of JMT101 combined with osimertinib versus osimertinib as first-line treatment for advanced NSCLC with EGFR sensitive mutations; To evaluate the pharmacokinetic characteristics of JMT101; To evaluate the immunogenicity of JMT101; To analyze the correlation between EGFR mutation status, expression level, amplification status and clinical efficacy; To analyze the correlation between tumor-related gene changes and clinical efficacy.

Start Date17 Oct 2024

Sponsor / Collaborator

Shanghai JMT Biological Technology Co Ltd

CTR20242512 / RecruitingPhase 1

一项单中心、随机、双盲、安慰剂对照、单次剂量递增、评价JMT202注射液在中国健康受试者中的安全性、耐受性、药代动力学和药效动力学特征的I期临床试验

[Translation] A single-center, randomized, double-blind, placebo-controlled, single-dose escalation phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JMT202 injection in healthy Chinese subjects

主要目的：评估在中国健康受试者中单次皮下注射JMT202注射液的安全性和耐受性次要目的：评估在中国健康受试者中单次皮下注射JMT202注射液后的药代动力学特征、免疫原性和药效动力学特征

[Translation]

Primary objective: To evaluate the safety and tolerability of a single subcutaneous injection of JMT202 injection in healthy Chinese subjects Secondary objective: To evaluate the pharmacokinetic, immunogenicity and pharmacodynamic characteristics of JMT202 injection after a single subcutaneous injection in healthy Chinese subjects

Start Date23 Jul 2024

Sponsor / Collaborator

Shanghai JMT Biological Technology Co Ltd

NCT06564467 / Enrolling by invitationPhase 1

A Phase І, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMT202 Injection in Chinese Healthy Participants

This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JMT202 in Healthy Participants.

Start Date23 Jul 2024

Sponsor / Collaborator

Shanghai JMT Biological Technology Co Ltd

100 Clinical Results associated with Shanghai JMT Biological Technology Co Ltd

Login to view more data

0 Patents (Medical) associated with Shanghai JMT Biological Technology Co Ltd

Login to view more data

1

News (Medical) associated with Shanghai JMT Biological Technology Co Ltd

30 Sep 2024

·endpts.com

CSPC, Alphamab Oncology make an ADC deal; Visen’s IPO in Hong Kong

Plus, news about Sequentia Biotech: CSPC, Alphamab Oncology ink ADC deal: CSPC Pharmaceutical’s JMT-Bio Technology said it will pay RMB 400 million ($57 million) upfront and up to RMB 3.08 billion ($439 million) in total for access in China to Alphamab’s anti-HER2 bispecific ADC, called JSKN003. Visen files for IPO in Hong Kong: The six-year-old company on Monday filed to go public on the Hong Kong Stock Exchange. The Shanghai-based drug developer is working to get Ascendis’ FDA-approved pediatric growth hormone deficiency drug greenlit in China. Sequentia Biotech raises €10M: The Spanish bioinformatics company nabbed the Series A from Seventure Partners and EIC Fund.

IPODrug ApprovalADC

100 Deals associated with Shanghai JMT Biological Technology Co Ltd

Login to view more data

100 Translational Medicine associated with Shanghai JMT Biological Technology Co Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

IND Application

Phase 1

2

1

Phase 2

Phase 3

3

1

Approved

Other

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Narlumosbart ( RANKL )	Bone metastases More	Phase 3
Anbenitamab ( HER2 )	HER2 Positive Breast Cancer More	Phase 3
Docetaxel albumin bound ( Tubulin )	Squamous non-small cell lung cancer More	Phase 2/3
Becotatug ( EGFR )	Locally Advanced Lung Non-Small Cell Carcinoma More	Phase 2
JMT-601 ( CD20 x SIRPα )	B-cell lymphoma recurrent More	Phase 1